Matching articles for "Xocova"
Ensitrelvir (Xocova) for Post-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • July 20, 2026; (Issue 1759)
The FDA has approved ensitrelvir (Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis
of COVID-19 in patients ≥12 years old who had contact with
an infected individual....
The FDA has approved ensitrelvir (Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis
of COVID-19 in patients ≥12 years old who had contact with
an infected individual. Ensitrelvir is the first oral antiviral
drug to be approved in the US for this indication. The parenteral
monoclonal antibody combinations bamlanivimab and
etesevimab and casirivimab and imdevimab (REGEN-COV)
are no longer authorized for postexposure prophylaxis of
COVID-19 in the US.